ImmunityBio

ImmunityBio is a life sciences company that focuses on immunotherapy.[1]

History

ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong.[2]

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[3][4]

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates.[5] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[5]

Pipeline

COVID-19 (SARS-CoV-2)

ImmunityBio is developing several vaccine candidates against COVID-19. Their vaccines are under Phase I, II, III stage in various countries.

  1. Adenovirus Type 5 + DNA (hAd5)
  2. Nanostructured lipid carriers (NLCs) + RNA (saRNA)[6]
  3. Yeast + RBD + Adjuvants[7]

References
  1. "ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New 'Magnitude of Benefit' in Patients with BCG Unresponsive Bladder Cancer". finance.yahoo.com. Retrieved 2022-02-19.
  2. "Oral COVID-19 vaccine being tested in Los Angeles-area research center". www.cbsnews.com. Retrieved 2021-04-14.
  3. "NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.
  4. Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
  5. Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
  6. "Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination". News-Medical.net. 2021-12-05. Retrieved 2022-02-19.
  7. "ImmunityBio S4 Filing". 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.